Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of FF/VI vs FP in Asthma with EIB
NCT02730351Phase 4Completed
- Sponsor
- GSK
- Start
- May 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of fluticasone furoate + vilanterol in asthma and Exercise-induced bronchoconstriction (EIB) (2 arms), sponsored by GSK. Primary endpoint: Maximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours Post Evening Dose. Started May 2016; status: completed.
02
Drugs
fluticasone furoate + vilanterol
03
Conditions
asthmaExercise-induced bronchoconstriction (EIB)
Beyond the preview
Go deeper on NCT02730351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730351.